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CYCLES: A CASE STUDY OF 
HOW PHARMACEUTICALS ARE 
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PREVIOUS RESEARCH – PRODUCT
LIFE CYCLE
PHARMACEUTICAL MARKET
 Moss (2008) states that research has focused on 
consumer products and brands disregarding other 
products and brands such as pharmaceuticals. 
 Highly competitive non assembled global industry
 In 2007 the top 10 pharmaceutical companies had a 
combined sales of just under £150 billion and 
commanded 45% market share
 2 of these were UK companies – AstraZeneca and 
GlaxoSmithKline
PHARMACEUTICAL MARKET CONTINUED
 In 2008 £4 billion was spent on R&D however this 
was expected to decrease due to the financial climate
 Patent Expiration – Major Problem
 UK patents last for 20 years from application
 5 year extension can be applied for
 Generics enter the market
 NHS and other health/government organisations 
always looking at ways to curb the rising cost of 
healthcare
PHARMACEUTICAL MARKET CONTINUED
 A branded drug is one made by a specific 
pharmaceutical company and is therefore given a 
name. The generic is the key compound that 
makes up the drug. In some cases the company 
can market both the branded and generic to 
appeal to a wider audience. An example is 
Sertraline.
 Brand name – Lustral by Pfizer
 Generic name – Sertraline.
RESEARCH PROJECT - AIMS
 Aims
1. To classify the patterns that are exhibited during the 
product lifecycle of pharmaceutical drugs
2. Model these patterns 
3. Forecast the patterns
4. This will allow us to discover which forecasting methods 






RESEARCH PROJECT – THE DATA
 JIGSAW database
 Established in 1985 by ISIS research for the 
purposes of academic research
 Data from 1987 -2008
 2.57 million script records
 Self Report Questionnaires from GP’s
 Data is specifically relating to what drugs are 
prescribed
PHARMACEUTICAL LIFE CYCLE TYPES
 Based on the current research there are three 
types of pharmaceutical life cycle including both 
a branded and a generic strand.
 Branded then Generic
 High Branded Low Generic


















Total Number of 
Prescriptions 
(Rx) between 
1987 and 2008 Sources 





inflammatory 13307-86-5 GB 1132318 Geigy 1968 1983 NA 167190
Espacenet, Patent 
Archives






Enzyme (ACE) 7475847-73-3 EP12401 Merck and Co 1983 1995 NA 16410 Espacenet 
Losec Omeprazole Acid Reflux 73590-58-6 EP5129 Haessle AB 1979 1999 2005 47751
USPTO, Espacenet, 
MPA services













inflammatory 22204-53-1 GB 1291386 Syntex 1972 1988 NA 65817
MPA Services, 
Espacenet
Prothiaden Dosulepin** Anti-depressant 113-53-1 GB 1013574 Spofa 1965 1978 NA 45982
Espacenet, MPA 
Sernices




Serevent Salmeterol Asthma 89365-50-4 GB2176476 Glaxo 1987 2004 NA 10995
Merck Index, 
Espacenet




Tagamet Cimetidine Acid reflux 51481-61-9 GB1338169
SmithKline & 













Disease 66357-35-5 GB 1565966
Allen & 























fees) NA 37264 USPTO, Espacenet 















Total Number of 
Prescriptions 
(Rx) between 
1987 and 2008 Sources 
Adalat Nifedipine Hypertension 21829-25-4 GB1173862
Farbenfabriken 
Bayer AG 1969 1988 NA 26905
Espacenet, Merck Index, 
MPA services, Patent 
Archive
Becotide Beclomethasone Asthma 08/09/5534 GB912378 Merck and co 1962 1982 NA 43184 Patent Archives, Espacenet
Feldene Piroxicam
Anti-




54-31-9 GB936417 (fru) Hoechst AG 1963 1983
2016-88-8 GB1066855 (am) Merck and co 1967 1987
GNT
Glyceryl 
trinitrate Angina 55-63-0 NA NA Pre 1900 NA NA 23520
Walter Sneader, Drug 
Discovery: A History. John 
Wiley & Sons (2005)
Maalox
Aluminium 











SA 1969 1989 NA 13963 Patent Archives, Espacenet
82115-62-6 US2565115 Squibb & Son 1951 Expired NA











AG 1936 Expired NA 14881 Merck Index, Espacenet
Tryptizol Amitriptyline Anti-depressant 50-48-6 GB858187 Hoffman and La Roche 1961 Expired NA 24354 Patent Archives, Espacenet
Ventolin Salbutamol Asthma 18559-94-9 GB1200886
Allen & 
































Total Number of 
Prescriptions (Rx) 
between 1987 and 
2008 Sources 
Aprinox Bendroflumethiazide Hypertension 78-48-3 GB 863474
F. Lund and W. O. 















Relief 125-28-0 NA NA
Introduced 
1911 NA NA 13592 Merck Index
Flexin Indocid
Analgesic/Anti-
inflammatory 53-86-1 GB 997638 Merck and Co 1965 1978 NA 21409
Patent Archives, 
Espacenet






retention 54-31-9 GB936417 Hoechst AG 1963 1983 NA 22037
Espacenet, Patent 
Archives
Panadol Paracetamol Analgesic 103-90-2 US2998450 Warner Lambert 1961 Expired NA 24722
Merck Index, 
Espacenet
Zydol Tramadol Analgesic 27203-92-5 GB997399
Chem Gruenenthal 
GMBH 1964 1984 NA 14306
Patent Archives, 
Espacenet
MODELS USED IN THE CURRENT RESEARCH
 Naïve Model
 Moving Average Model
 Single Exponential Smoothing (SES)
 Repeat Purchase Diffusion Model (RPDM)
 Bass Diffusion Model
RESULTS – BRANDED THEN GENERIC






ME(Bias) -83.11 -134.94 -127.28 -334.33 -327.50
RAE(Accuracy) 1.00 1.53 1.58 4.21 4.40
MSE(Uncertainty) 261458.16 371854.37 419259.71 1092619.18 1237103.57






ME(Bias) -82.12 -134.75 -87.81 -56.58 -5.21
RAE(Accuracy) 1.00 1.48 1.51 3.49 3.73





























RESULTS – HIGH BRANDED LOW GENERIC
Drug RPDM Bass
































ME(Bias) -58.47 -123.74 -122.43 -365.81 -309.11
RAE(Accuracy) 1.00 1.85 1.78 4.81 4.80
MSE(Uncertainty) 155842.58 229410.24 357958.64 599272.17 703422.40






ME(Bias) -7.48 -9.38 -10.15 -17.05 -2.23
RAE(Accuracy) 1.00 1.21 1.40 2.40 2.61
MSE(Uncertainty) 6350.14 7285.49 13739.63 17616.17 21974.55


























ME(Bias) -36.79 -102.30 -79.08 -292.06 -276.98
RAE(Accuracy) 1.00 2.15 1.73 5.35 5.59
MSE(Uncertainty) 21199.25 108823.30 46540.67 348546.20 353349.73






ME(Bias) -50.81 -51.68 -68.75 -26.79 105.53
RAE(Accuracy) 1.00 1.23 1.53 2.59 2.86
MSE(Uncertainty) 190881.37 206286.76 509913.82 1300270.10 1700203.04























ME(Bias) -83.11 -76.01 -68.93 -61.81 -54.71 -47.61 -40.48 -33.42 -26.32 -19.22 -12.12
RAE(Accuracy) 1.00 0.98 0.98 1.00 1.02 1.06 1.09 1.14 1.19 1.24 1.32
























ME(Bias) -82.12 -77.98 -73.84 -69.71 -65.57 -61.43 -56.56 -53.15 -49.01 -44.87 -40.73
RAE(Accuracy) 1.00 0.95 0.90 0.86 0.82 0.79 0.79 0.79 0.81 0.85 0.91
MSE(Uncertainty) 198214.64 185541.65 175497.55 168082.35 163296.04 161138.62 161684.64 164710.47 170439.73 178797.89 189784.94
Drift
























ME(Bias) -58.47 -51.89 -45.30 -38.71 -32.13 -25.54 -18.96 -12.37 -5.78 0.80 7.39
RAE(Accuracy) 1.00 0.95 0.90 0.87 0.84 0.83 0.84 0.87 0.92 0.97 1.04
























ME(Bias) -7.48 -7.14 -6.79 -6.44 -6.10 -5.75 -5.41 -5.06 -4.71 -4.37 -4.02
RAE(Accuracy) 1.00 0.99 1.00 1.03 1.07 1.11 1.17 1.22 1.28 1.35 1.41
MSE(Uncertainty) 6350.14 5954.06 5677.42 5520.23 5482.48 5564.18 5765.32 6085.90 6525.93 7085.40 7764.31
Drift
























ME(Bias) -36.79 -32.56 -28.34 -24.12 -19.89 -15.67 -11.44 -7.22 -3.00 1.23 5.45
RAE(Accuracy) 1 0.95 0.91 0.88 0.87 0.87 0.88 0.91 0.97 1.04 1.12
























ME(Bias) -50.81 -48.77 -46.73 -44.68 -42.64 -40.60 -38.56 -36.52 -34.48 -32.44 -30.40
RAE(Accuracy) 1.00 0.97 0.95 0.95 0.95 0.96 0.98 1.01 1.04 1.07 1.12
MSE(Uncertainty) 190881.37 173568.10 159902.37 149884.20 143513.58 140790.50 141714.98 146287.01 154506.59 166373.72 181888.40
Drift
CONCLUSIONS
 GP’s within the UK have a tendency to prescribe branded 
and generic drugs differently
 Simpler models forecast pharmaceutical life cycles with a 
greater level of accuracy than more complex ones.
 Most accurate of the current research = Naïve+%drift
 Aaker and Jacobson (1987) found that when modelling 
market share using the naive market share model, its 
predictive power was relatively high. 
 Brodie & de Kluyver (1987) found that a number of 
econometric market share models perform no better than a 
'naive' model.' 
CONCLUSIONS
 This research provides a basis for the NHS in 
employing any cost saving techniques when 
looking at how different pharmaceuticals are 
prescribed, and forecasting how they may be 
prescribed in the future
 As for pharmaceutical companies this research 
will allow them to discover, when it is best in the 
life cycle of the branded pharmaceutical to 
introduce strategies to prolong its life cycle and 
slow down the number of generic prescriptions 
written
THANK YOU
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